<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90900">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142153</url>
  </required_header>
  <id_info>
    <org_study_id>F901318-01-01-14</org_study_id>
    <secondary_id>2014-000823-25</secondary_id>
    <nct_id>NCT02142153</nct_id>
  </id_info>
  <brief_title>F901318 Single Ascending Dose Study in Healthy Male Volunteers</brief_title>
  <official_title>F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F2G Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>F2G Ltd.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      F901318 is a potent new antifungal agent for the treatment of systemic fungal infections.
      This study will test it for the first time in man with the objective of assessing its
      safety, tolerability and pharmacokinetic profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, placebo controlled, ascending single intravenous dose, sequential group study.
       Forty subjects will be studied in 5 cohorts (Groups A to E), each group consisting of 8
      subjects.  Each subject will be on study for approximately 6 weeks. Each subject will
      participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from
      Day -1 (the day before dosing) to Day 6 (120 hours post-dose).  Each cohort will be dosed in
      a leading edge design in which two subjects will receive study drug (1 active and 1 placebo)
      on the first dosing day, and the last 6 will receive study drug (active or placebo) on the
      second dosing day.

      All subjects will return for a post-study visit 8 to 10 days after the dose of study
      medication.

      Cohorts will be dosed at 2 weekly intervals.  There will be a review of safety and
      pharmacokinetic data prior to each dose escalation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Single dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be collected from the time of screening until the final study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with significant Clinical safety labs and ECG abnormalities</measure>
    <time_frame>Single dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>From screening until final study visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Single dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples (6 mL) for analysis of F901318 plasma concentration will be drawn pre-dose and at 1h, 2h, 3h and 4h and then 4.25, 4.5, 5.0, 5.5, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96 and 120 hours following the start of the infusion. (20 samples).</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <arm_group>
    <arm_group_label>F901318 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 mg/kg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F901318 0.75 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.75 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F901318 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1.5 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F901318 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 3 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F901318 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 5 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous infusion over 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F901318</intervention_name>
    <description>Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.
Pharmacokinetic profile</description>
    <arm_group_label>F901318 0.25 mg/kg</arm_group_label>
    <arm_group_label>F901318 0.75 mg/kg</arm_group_label>
    <arm_group_label>F901318 1.5 mg/kg</arm_group_label>
    <arm_group_label>F901318 mg/kg</arm_group_label>
    <arm_group_label>F901318 5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities</description>
    <arm_group_label>0.25 mg/kg placebo</arm_group_label>
    <arm_group_label>Placebo 0.75 mg/kg</arm_group_label>
    <arm_group_label>Placebo 1.5 mg/kg</arm_group_label>
    <arm_group_label>Placebo 3 mg/kg</arm_group_label>
    <arm_group_label>Placebo 5 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects will be males of any ethnic origin between 18 and 45 years of age and
             weighing 60-90 kg inclusive

          2. Subjects must be in good health, as determined by a medical history, physical
             examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations
             (congenital non haemolytic hyperbilirubinaemia is acceptable)

          3. Subjects will have given their written informed consent to participate in the study
             and to abide by the study restrictions

        Exclusion Criteria:

          1. Male subjects who are not, or whose partners are not willing to use appropriate
             contraception (such as a condom) with established use of oral, injected or implanted
             hormonal contraceptive, intrauterine device or diaphragm with spermicide for three
             months after the last dose

          2. Subjects who have received any prescribed systemic or topical medication within 14
             days of dosing with study drug unless in the opinion of the Investigator and the
             Medical Monitor the medication will not interfere with the study procedures or
             compromise safety

          3. Subjects who have used any non-prescribed systemic or topical medication (including
             herbal remedies) within 7 days of dosing with study drug (with the exception of
             vitamin/mineral supplements) unless in the opinion of the Investigator and the
             Medical Monitor the medication will not interfere with the study procedures or
             compromise safety

          4. Subjects who have received any medications, including St John's Wort, known to
             chronically alter drug absorption or elimination processes within 30 days of dosing
             with study drug unless in the opinion of the Investigator and the Medical Monitor the
             medication will not interfere with the study procedures or compromise safety

          5. Subjects who are still participating in a clinical study (e.g. attending follow-up
             visits) or who have participated in a clinical study involving administration of an
             investigational drug (new chemical or biological entity) in the past 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Febbraro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salvatore Febbraro, MD</last_name>
    <phone>+44 (0) 1443 690977</phone>
    <email>salvatore.febbraro@simbec.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Mid Glamorgan</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Salvatore Febbraro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>May 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in man</keyword>
  <keyword>Antifungal</keyword>
  <keyword>Intravenous infusion</keyword>
  <keyword>Healthy volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
